Pay in 4 interest-free payments of $5.19 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
If your target dose is 2 mg, you draw 20 units
Last reviewed: November 16, 2025 Nuvaxovid is the brand name of the adjuvanted protein subunit COVID-19 vaccine developed by Novavax and commercialized by Sanofi beginning in the 202526 season
Theoretical considerations include: Potential interactions requiring monitoring: Other fat-loss agents or thermogenics (additive effects), growth hormone or growth hormone secretagogues (mechanism overlap), medications affecting glucose metabolism (monitor blood sugar despite AOD-9604s neutral glycemic effects)
Its inclusion allows repeated access to a sealed multi-dose vial within a defined window, distinguishing this product from preservative-free sterile water, which is strictly single-use
PubMed laboratory research record [PMID: 28855839] PubMed record related to this compound for laboratory literature review
- Medicare and most commercial payers cover the contrast agent's fee when medical necessity is demonstrated
